YOUR BUSINESS AUTHORITY
Springfield, MO
A study showed Novavax's COVID-19 vaccine had a 100% efficacy against the original strain of the coronavirus and 93% efficacy against more worrisome variants that have subsequently appeared.
The study, which involved nearly 30,000 volunteers in the United States and Mexico, also showed it was safe for users. Like other COVID-19 vaccines, it caused headaches, chills and muscle aches after injection, but few of these side effects were considered serious or severe.
The company says it intends to file for authorization from regulators in the U.S., Europe and the United Kingdom later this summer. Novavax says it will be able to deliver 100 million doses per month by the end of September and 150 million doses per month by the end of the year.
Read more from NPR.
Organizers hope to bolster client traffic to center city businesses.
SBJ announces executive newsroom hires
Timeshare exit company owner sentenced for tax evasion
Trump, fast-food companies among targets of X redirects
Stockton district names next superintendent
State awards Springfield $4.6M for wastewater system improvements
Council modifies data center definitions bill, extends moratorium into next year